Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update
Telo Genomics (OTCQB: TDSGF) has announced the relocation of its clinical laboratories from the MaRS startup incubation hub to a new, larger state-of-the-art facility at 555 Richmond Street West in Toronto. The expansion comes in response to increasing demand for their diagnostic tests and growing volume of clinical and research samples.
The company, which specializes in diagnostic and prognostic tests through telomere analysis, began operations at the new facility on September 29, 2025. Additionally, the company announced the resignation of Hugh Rogers from its Board of Directors.
Telo Genomics (OTCQB: TDSGF) ha annunciato il trasferimento dei laboratori clinici dall'incubatore di startup MaRS a una nuova, più grande e all'avanguardia struttura situata al 555 della strada Richmond West a Toronto. L'espansione risponde alla crescente domanda dei loro test diagnostici e all'aumento del volume di campioni clinici e di ricerca.
L'azienda, che si occupa di test diagnostici e prognostici tramite analisi dei telomeri, ha avviato le operazioni presso la nuova struttura il 29 settembre 2025. Inoltre, l'azienda ha annunciato le dimissioni di Hugh Rogers dal Consiglio di Amministrazione.
Telo Genomics (OTCQB: TDSGF) ha anunciado el traslado de sus laboratorios clínicos desde el hub de incubación MaRS a una nueva instalación más grande y de última generación en 555 Richmond Street West, Toronto. La expansión responde a la creciente demanda de sus pruebas diagnósticas y al aumento del volumen de muestras clínicas y de investigación.
La empresa, que se especializa en pruebas diagnósticas y pronósticas mediante análisis de telómeros, comenzó a operar en la nueva instalación el 29 de septiembre de 2025. Además, la compañía anunció la renuncia de Hugh Rogers a su Junta Directiva.
Telo Genomics (OTCQB: TDSGF)는 MaRS 스타트업 인큐베이터 허브에서 임상 연구실을 새로운 더 크고 최첨단 시설인 토론토 555 Richmond Street West로 이전했다고 발표했습니다. 이 확장은 진단 검사에 대한 증가하는 수요와 임상 및 연구 샘플의 증가에 대한 반응입니다.
Telomere 분석을 통한 진단 및 예후 검사에 특화된 이 회사는 2025년 9월 29일에 새 시설에서 운영을 시작했습니다. 또한 Hugh Rogers가 이사회에서 사임하기로 했다고 발표했습니다.
Telo Genomics (OTCQB: TDSGF) a annoncé le déménagement de ses laboratoires cliniques du hub d'incubation MaRS vers une nouvelle installation plus grande et à la pointe de la technologie, située au 555 Richmond Street West à Toronto. Cette expansion répond à la demande croissante pour leurs tests diagnostiques et à l'augmentation du volume d'échantillons cliniques et de recherche.
L'entreprise, spécialisée dans les tests diagnostiques et pronostiques par analyse des télomères, a commencé ses opérations dans cette nouvelle installation le 29 septembre 2025. De plus, la société a annoncé la démission de Hugh Rogers du conseil d'administration.
Telo Genomics (OTCQB: TDSGF) hat den Umzug seiner klinischen Labore vom MaRS-Startup-Inkubator in eine neue, größere, hochmoderne Einrichtung in der 555 Richmond Street West in Toronto bekannt gegeben. Die Expansion erfolgt aufgrund der wachsenden Nachfrage nach ihren Diagnosetests und dem steigenden Volumen an klinischen und Forschungsproben.
Das Unternehmen, das sich auf diagnostische und prognostische Tests durch Telomeranalyse spezialisiert hat, nahm den Betrieb in der neuen Einrichtung am 29. September 2025 auf. Außerdem gab das Unternehmen den Rücktritt von Hugh Rogers aus dem Vorstand bekannt.
أعلنت Telo Genomics (OTCQB: TDSGF) عن نقل مختبراتها السريرية من محور احتضان MaRS إلى منشأة جديدة أكبر وأكثر تطوراً في 555 Richmond Street West في تورنتو. يأتي التوسع استجابة للطلب المتزايد على اختباراتهم التشخيصية وارتفاع حجم العينات السريرية والبحثية.
بدأت الشركة، المتخصصة في الاختبارات التشخيصية والتنبؤية من خلال تحليل التيلوميرات، عملياتها في المنشأة الجديدة في 29 سبتمبر 2025. كما أعلنت الشركة عن استقالة هيو روجرز من مجلس الإدارة.
Telo Genomics（OTCQB：TDSGF）宣布将其临床实验室从 MaRS 初创孵化中心迁至多伦多 555 Richmond Street West 的一座更大、更先进的新设施。此次扩张是为了应对对其诊断测试需求的增加以及临床与研究样本量的增长。
这家专门通过端粒分析进行诊断和预后测试的公司，已于 2025 年 9 月 29 日 在新设施开始运营。此外，公司宣布 Hugh Rogers 将从董事会辞任。
- Expansion to larger, state-of-the-art laboratory facility
- Growing demand for diagnostic tests
- Increasing volume of clinical and research samples
- None.
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announces the relocation and expansion of its clinical laboratories and offices from the MaRS startup incubation hub into a new, state-of-the-art clinical laboratory space in the Greater Toronto Area.
The relocation reflects the Company's continued progress leading to an expanding volume of clinical and research samples, as well as a commitment to thoughtful governance and positioning the company for long-term success. The Company started operating at the newly renovated office and laboratory space at 555 Richmond Street West, Toronto, M5V 3B1, effective September 29th.
"This move marks a significant milestone for Telo Genomics, driven by the growing demand for our advanced diagnostic tests," said Guido Baechler, Executive Chairman of the Board. "Our new, larger laboratory empowers us to scale our operations, accelerate our research programs, and ultimately, better serve our clinical partners. This facility is more than a new address; it's a launchpad for the next phase of our company's growth and innovation."
In a separate corporate update, the Company also announced the resignation of Hugh Rogers as a director of the Company. The Board of Directors thanks Mr. Rogers for his valuable contributions and guidance during his tenure and wishes him the best in his future endeavors.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Brett Maas
Managing Partner
(646) 536-7331
Brett@HaydenIR.com
7320 E. Butherus Drive
Scottsdale, AZ 85260
haydenir.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268471
FAQ
Why did Telo Genomics (TDSGF) relocate its clinical laboratories in September 2025?
Where is Telo Genomics' new laboratory facility located?
When did Telo Genomics begin operations at their new Toronto facility?
What changes occurred in Telo Genomics' Board of Directors in September 2025?
